世界の経皮治療システム（TTS）市場予測（～2028年）：サリチル酸メチル、ニトログリセリン、フェンタニル、ニコチン、リバスチグミン、エストラジオール、その他

• 英文タイトル：Global Transdermal Therapeutic Systems (TTS) Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

• レポートコード：GIR-22E8977 • 出版社/出版日：GlobalInfoResearch / 2022年5月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

経皮治療システム（TTS）市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界の経皮治療システム（TTS）の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 経皮治療システム（TTS）市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・サリチル酸メチル、ニトログリセリン、フェンタニル、ニコチン、リバスチグミン、エストラジオール、その他 用途別セグメントは次のように区分されます。 ・OTCチャネル、小売チャネル、Eコマースチャネル 世界の経皮治療システム（TTS）市場の主要な市場プレーヤーは以下のとおりです。 ・Hisamitsu、Mylan、GSK、Novartis、Teve (Actavis)、Nitto Denko、Johnson & Johnson、Lohmann、Teikoku Seiyaku、Pfizer、Bayer、Lingrui、Sanofi、UCB Pharma、Dr. Reddy's Laboratories、Qizheng、Endo、Mundipharma、Huarun 999、Haw Par、Nichiban、Mentholatum Company、Laboratoires Genevrier、Beijing Tide Pharmaceutical、Luye Pharma Group 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、経皮治療システム（TTS）製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な経皮治療システム（TTS）メーカーの企業概要、2019年～2022年までの経皮治療システム（TTS）の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な経皮治療システム（TTS）メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別経皮治療システム（TTS）の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの経皮治療システム（TTS）の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での経皮治療システム（TTS）市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および経皮治療システム（TTS）の産業チェーンを掲載しています。 ・第13、14、15章では、経皮治療システム（TTS）の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Hisamitsu、Mylan、GSK、Novartis、Teve (Actavis)、Nitto Denko、Johnson & Johnson、Lohmann、Teikoku Seiyaku、Pfizer、Bayer、Lingrui、Sanofi、UCB Pharma、Dr. Reddy's Laboratories、Qizheng、Endo、Mundipharma、Huarun 999、Haw Par、Nichiban、Mentholatum Company、Laboratoires Genevrier、Beijing Tide Pharmaceutical、Luye Pharma Group ・メーカー別市場シェア ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：サリチル酸メチル、ニトログリセリン、フェンタニル、ニコチン、リバスチグミン、エストラジオール、その他 ・用途別分析2017年-2028年：OTCチャネル、小売チャネル、Eコマースチャネル ・経皮治療システム（TTS）の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ ・経皮治療システム（TTS）のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア ・経皮治療システム（TTS）のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア ・経皮治療システム（TTS）の南米市場規模2017年-2028年：ブラジル、アルゼンチン ・経皮治療システム（TTS）の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Transdermal Therapeutic Systems (TTS) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Transdermal Therapeutic Systems (TTS) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. OTC Channel accounting for % of the Transdermal Therapeutic Systems (TTS) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Methyl Salicylate segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Transdermal Therapeutic Systems (TTS) include Hisamitsu, Mylan, GSK, Novartis, and Teve (Actavis), etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Transdermal Therapeutic Systems (TTS) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Methyl Salicylate
Nitroglycerin
Fentanyl
Nicotine
Rivastigmine
Estradiol
Others
Market segment by Application can be divided into
OTC Channel
Retail Channel
E-Commerce Channel
The key market players for global Transdermal Therapeutic Systems (TTS) market are listed below:
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Nitto Denko
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Pfizer
Bayer
Lingrui
Sanofi
UCB Pharma
Dr. Reddy’s Laboratories
Qizheng
Endo
Mundipharma
Huarun 999
Haw Par
Nichiban
Mentholatum Company
Laboratoires Genevrier
Beijing Tide Pharmaceutical
Luye Pharma Group
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Transdermal Therapeutic Systems (TTS) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Transdermal Therapeutic Systems (TTS), with price, sales, revenue and global market share of Transdermal Therapeutic Systems (TTS) from 2019 to 2022.
Chapter 3, the Transdermal Therapeutic Systems (TTS) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Transdermal Therapeutic Systems (TTS) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Transdermal Therapeutic Systems (TTS) market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Transdermal Therapeutic Systems (TTS).
Chapter 13, 14, and 15, to describe Transdermal Therapeutic Systems (TTS) sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Transdermal Therapeutic Systems (TTS) Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Transdermal Therapeutic Systems (TTS) Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Methyl Salicylate
1.2.3 Nitroglycerin
1.2.4 Fentanyl
1.2.5 Nicotine
1.2.6 Rivastigmine
1.2.7 Estradiol
1.2.8 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Transdermal Therapeutic Systems (TTS) Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 OTC Channel
1.3.3 Retail Channel
1.3.4 E-Commerce Channel
1.4 Global Transdermal Therapeutic Systems (TTS) Market Size & Forecast
1.4.1 Global Transdermal Therapeutic Systems (TTS) Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Transdermal Therapeutic Systems (TTS) Sales in Volume (2017-2028)
1.4.3 Global Transdermal Therapeutic Systems (TTS) Price (2017-2028)
1.5 Global Transdermal Therapeutic Systems (TTS) Production Capacity Analysis
1.5.1 Global Transdermal Therapeutic Systems (TTS) Total Production Capacity (2017-2028)
1.5.2 Global Transdermal Therapeutic Systems (TTS) Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Transdermal Therapeutic Systems (TTS) Market Drivers
1.6.2 Transdermal Therapeutic Systems (TTS) Market Restraints
1.6.3 Transdermal Therapeutic Systems (TTS) Trends Analysis
2 Manufacturers Profiles
2.1 Hisamitsu
2.1.1 Hisamitsu Details
2.1.2 Hisamitsu Major Business
2.1.3 Hisamitsu Transdermal Therapeutic Systems (TTS) Product and Services
2.1.4 Hisamitsu Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Mylan
2.2.1 Mylan Details
2.2.2 Mylan Major Business
2.2.3 Mylan Transdermal Therapeutic Systems (TTS) Product and Services
2.2.4 Mylan Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Transdermal Therapeutic Systems (TTS) Product and Services
2.3.4 GSK Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Transdermal Therapeutic Systems (TTS) Product and Services
2.4.4 Novartis Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Teve (Actavis)
2.5.1 Teve (Actavis) Details
2.5.2 Teve (Actavis) Major Business
2.5.3 Teve (Actavis) Transdermal Therapeutic Systems (TTS) Product and Services
2.5.4 Teve (Actavis) Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Nitto Denko
2.6.1 Nitto Denko Details
2.6.2 Nitto Denko Major Business
2.6.3 Nitto Denko Transdermal Therapeutic Systems (TTS) Product and Services
2.6.4 Nitto Denko Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Johnson & Johnson
2.7.1 Johnson & Johnson Details
2.7.2 Johnson & Johnson Major Business
2.7.3 Johnson & Johnson Transdermal Therapeutic Systems (TTS) Product and Services
2.7.4 Johnson & Johnson Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Lohmann
2.8.1 Lohmann Details
2.8.2 Lohmann Major Business
2.8.3 Lohmann Transdermal Therapeutic Systems (TTS) Product and Services
2.8.4 Lohmann Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Teikoku Seiyaku
2.9.1 Teikoku Seiyaku Details
2.9.2 Teikoku Seiyaku Major Business
2.9.3 Teikoku Seiyaku Transdermal Therapeutic Systems (TTS) Product and Services
2.9.4 Teikoku Seiyaku Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Transdermal Therapeutic Systems (TTS) Product and Services
2.10.4 Pfizer Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Bayer
2.11.1 Bayer Details
2.11.2 Bayer Major Business
2.11.3 Bayer Transdermal Therapeutic Systems (TTS) Product and Services
2.11.4 Bayer Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Lingrui
2.12.1 Lingrui Details
2.12.2 Lingrui Major Business
2.12.3 Lingrui Transdermal Therapeutic Systems (TTS) Product and Services
2.12.4 Lingrui Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Sanofi
2.13.1 Sanofi Details
2.13.2 Sanofi Major Business
2.13.3 Sanofi Transdermal Therapeutic Systems (TTS) Product and Services
2.13.4 Sanofi Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 UCB Pharma
2.14.1 UCB Pharma Details
2.14.2 UCB Pharma Major Business
2.14.3 UCB Pharma Transdermal Therapeutic Systems (TTS) Product and Services
2.14.4 UCB Pharma Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Dr. Reddy’s Laboratories
2.15.1 Dr. Reddy’s Laboratories Details
2.15.2 Dr. Reddy’s Laboratories Major Business
2.15.3 Dr. Reddy’s Laboratories Transdermal Therapeutic Systems (TTS) Product and Services
2.15.4 Dr. Reddy’s Laboratories Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Qizheng
2.16.1 Qizheng Details
2.16.2 Qizheng Major Business
2.16.3 Qizheng Transdermal Therapeutic Systems (TTS) Product and Services
2.16.4 Qizheng Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 Endo
2.17.1 Endo Details
2.17.2 Endo Major Business
2.17.3 Endo Transdermal Therapeutic Systems (TTS) Product and Services
2.17.4 Endo Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18 Mundipharma
2.18.1 Mundipharma Details
2.18.2 Mundipharma Major Business
2.18.3 Mundipharma Transdermal Therapeutic Systems (TTS) Product and Services
2.18.4 Mundipharma Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19 Huarun 999
2.19.1 Huarun 999 Details
2.19.2 Huarun 999 Major Business
2.19.3 Huarun 999 Transdermal Therapeutic Systems (TTS) Product and Services
2.19.4 Huarun 999 Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20 Haw Par
2.20.1 Haw Par Details
2.20.2 Haw Par Major Business
2.20.3 Haw Par Transdermal Therapeutic Systems (TTS) Product and Services
2.20.4 Haw Par Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21 Nichiban
2.21.1 Nichiban Details
2.21.2 Nichiban Major Business
2.21.3 Nichiban Transdermal Therapeutic Systems (TTS) Product and Services
2.21.4 Nichiban Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22 Mentholatum Company
2.22.1 Mentholatum Company Details
2.22.2 Mentholatum Company Major Business
2.22.3 Mentholatum Company Transdermal Therapeutic Systems (TTS) Product and Services
2.22.4 Mentholatum Company Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.23 Laboratoires Genevrier
2.23.1 Laboratoires Genevrier Details
2.23.2 Laboratoires Genevrier Major Business
2.23.3 Laboratoires Genevrier Transdermal Therapeutic Systems (TTS) Product and Services
2.23.4 Laboratoires Genevrier Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.24 Beijing Tide Pharmaceutical
2.24.1 Beijing Tide Pharmaceutical Details
2.24.2 Beijing Tide Pharmaceutical Major Business
2.24.3 Beijing Tide Pharmaceutical Transdermal Therapeutic Systems (TTS) Product and Services
2.24.4 Beijing Tide Pharmaceutical Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.25 Luye Pharma Group
2.25.1 Luye Pharma Group Details
2.25.2 Luye Pharma Group Major Business
2.25.3 Luye Pharma Group Transdermal Therapeutic Systems (TTS) Product and Services
2.25.4 Luye Pharma Group Transdermal Therapeutic Systems (TTS) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Transdermal Therapeutic Systems (TTS) Breakdown Data by Manufacturer
3.1 Global Transdermal Therapeutic Systems (TTS) Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Transdermal Therapeutic Systems (TTS) Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Transdermal Therapeutic Systems (TTS)
3.4 Market Concentration Rate
3.4.1 Top 3 Transdermal Therapeutic Systems (TTS) Manufacturer Market Share in 2021
3.4.2 Top 6 Transdermal Therapeutic Systems (TTS) Manufacturer Market Share in 2021
3.5 Global Transdermal Therapeutic Systems (TTS) Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Transdermal Therapeutic Systems (TTS) Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Transdermal Therapeutic Systems (TTS) Market Size by Region
4.1.1 Global Transdermal Therapeutic Systems (TTS) Sales in Volume by Region (2017-2028)
4.1.2 Global Transdermal Therapeutic Systems (TTS) Revenue by Region (2017-2028)
4.2 North America Transdermal Therapeutic Systems (TTS) Revenue (2017-2028)
4.3 Europe Transdermal Therapeutic Systems (TTS) Revenue (2017-2028)
4.4 Asia-Pacific Transdermal Therapeutic Systems (TTS) Revenue (2017-2028)
4.5 South America Transdermal Therapeutic Systems (TTS) Revenue (2017-2028)
4.6 Middle East and Africa Transdermal Therapeutic Systems (TTS) Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Transdermal Therapeutic Systems (TTS) Sales in Volume by Type (2017-2028)
5.2 Global Transdermal Therapeutic Systems (TTS) Revenue by Type (2017-2028)
5.3 Global Transdermal Therapeutic Systems (TTS) Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Transdermal Therapeutic Systems (TTS) Sales in Volume by Application (2017-2028)
6.2 Global Transdermal Therapeutic Systems (TTS) Revenue by Application (2017-2028)
6.3 Global Transdermal Therapeutic Systems (TTS) Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Transdermal Therapeutic Systems (TTS) Sales by Type (2017-2028)
7.2 North America Transdermal Therapeutic Systems (TTS) Sales by Application (2017-2028)
7.3 North America Transdermal Therapeutic Systems (TTS) Market Size by Country
7.3.1 North America Transdermal Therapeutic Systems (TTS) Sales in Volume by Country (2017-2028)
7.3.2 North America Transdermal Therapeutic Systems (TTS) Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Transdermal Therapeutic Systems (TTS) Sales by Type (2017-2028)
8.2 Europe Transdermal Therapeutic Systems (TTS) Sales by Application (2017-2028)
8.3 Europe Transdermal Therapeutic Systems (TTS) Market Size by Country
8.3.1 Europe Transdermal Therapeutic Systems (TTS) Sales in Volume by Country (2017-2028)
8.3.2 Europe Transdermal Therapeutic Systems (TTS) Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Transdermal Therapeutic Systems (TTS) Sales by Type (2017-2028)
9.2 Asia-Pacific Transdermal Therapeutic Systems (TTS) Sales by Application (2017-2028)
9.3 Asia-Pacific Transdermal Therapeutic Systems (TTS) Market Size by Region
9.3.1 Asia-Pacific Transdermal Therapeutic Systems (TTS) Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Transdermal Therapeutic Systems (TTS) Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Transdermal Therapeutic Systems (TTS) Sales by Type (2017-2028)
10.2 South America Transdermal Therapeutic Systems (TTS) Sales by Application (2017-2028)
10.3 South America Transdermal Therapeutic Systems (TTS) Market Size by Country
10.3.1 South America Transdermal Therapeutic Systems (TTS) Sales in Volume by Country (2017-2028)
10.3.2 South America Transdermal Therapeutic Systems (TTS) Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Transdermal Therapeutic Systems (TTS) Sales by Type (2017-2028)
11.2 Middle East & Africa Transdermal Therapeutic Systems (TTS) Sales by Application (2017-2028)
11.3 Middle East & Africa Transdermal Therapeutic Systems (TTS) Market Size by Country
11.3.1 Middle East & Africa Transdermal Therapeutic Systems (TTS) Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Transdermal Therapeutic Systems (TTS) Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Transdermal Therapeutic Systems (TTS) and Key Manufacturers
12.2 Manufacturing Costs Percentage of Transdermal Therapeutic Systems (TTS)
12.3 Transdermal Therapeutic Systems (TTS) Production Process
12.4 Transdermal Therapeutic Systems (TTS) Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Transdermal Therapeutic Systems (TTS) Typical Distributors
13.3 Transdermal Therapeutic Systems (TTS) Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

---